Build Investor Following

Spine-Tech, Inc.

Anticipating FDA approval of its BAK® Interbody Fusion System, Spine-Tech, Inc. hired Padilla Speer Beardsley to announce the FDA’s decision to the investment community and support the market launch of the product to surgeons and prospective patients. PSB used a two-pronged strategy to inform the business community of the FDA Review Panel’s decision to recommend approval of the BAK Interbody Fusion System; followed several months later by announcements to the consumer and business communities of FDA marketing clearance to launch the BAK in the United States. Spine-Tech’s announcements were covered by national and local publications including The Wall Street Journal, The New York Times and Reuters. Spine-Tech’s stock price rose significantly with each FDA announcement.